LENSKART · NSE
Lenskart Solutions Limited
₹707.2
+4.01% (+₹27.25)
Prev. close
₹679.95
Volume
2,56,90,503
Delivery %
64.2%
As of
18 Sept 2026
Price history
Morgan Stanley Analysis · Morgan Stanley India · 08 Sept 2026
“Overweight rating on Lenskart Solutions, priced at Rs 524 with a market capitalization of $10 billion.”
Published mid-session at 09:57 IST. Tracking counts only prices printed after publication — the chart's dashed divider marks that moment; earlier prices never count toward entry or results.
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Overweight rating on Lenskart Solutions, priced at Rs 524 with a market capitalization of $10 billion.” | Morgan Stanley AnalysisMorgan Stanley India | Lenskart Solutions | PENDING | ||||
“Overweight rating on Lenskart Solutions, priced at Rs 524 with a market capitalization of $10 billion.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
| “Bullish on Lenskart Solutions for intraday trading, recommending a buy at ₹662 with a target price of ₹716 and a stop lo…” | Sumeet BagadiaChoice Equity Broking | Lenskart Solutions | PENDING | ||||
Fundamentals
About Lenskart Solutions Limited
Lenskart Solutions Limited, a technology-driven eyewear company, engages in designing, manufacturing, branding, and retailing of eyewear products in India, Japan, Southeast Asia, the Middle East, and internationally. Its products include prescription eyeglasses, sunglasses, goggles, screen glasses, and other products, such as contact lenses and eyewear accessories, including frames for men, women, and kids. The company also engages in lens manufacturing, lens edging, lens design, frame design, frame manufacturing, and delivery. It operates as a direct-to-consumer company that designs and sells a wide range of eyewear products under the Lenskart and Owndays brands; and sub brands, including John Jacobs, Vincent Chase, Hooper, Lenskart Air, Hustlr, LPL, and Meller. It sells its products through online and offline channels, such as retail stores, websites, mobile applications, and other channels. The company also owns and operates eyewear retail stores in India and provides home eye check-up services. Lenskart Solutions Limited was incorporated in 2008 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Instruments & Supplies
CEO
Mr. Peyush Bansal
Headquarters
Gurugram
Employees
19,201
Website
lenskart.comExchange
View on NSE ↗Key stats
Market cap
₹1.22 L Cr
P/E ratio (TTM)
185.6
EPS (TTM)
₹3.81
Beta (1Y · daily vs NIFTY 50)
0.51
Shares float
72.02 Cr
EPS · quarter ended Jun 2026
₹1.28
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | — | — | ₹6,492.68 Cr | ₹8,814.04 Cr | |
| EBITDA | — | — | — | — | ₹1,327.82 Cr | ₹1,911.57 Cr |
| ₹29.00 Cr | ₹-102.00 Cr | ₹-64.00 Cr | ₹-17.00 Cr | ₹295.59 Cr | ₹493.61 Cr | |
| Diluted EPS | — | — | — | — | ₹1.72 | ₹2.9 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,802.00 Cr | ₹3,700.00 Cr | ₹9,462.00 Cr | ₹9,487.00 Cr | ₹10,390.00 Cr | ₹14,245.00 Cr | |
| — | — | — | — | ₹2,572.77 Cr | ₹3,096.60 Cr | |
| Stockholders' equity | ₹2,378.00 Cr | ₹2,933.00 Cr | ₹5,456.00 Cr | ₹5,482.00 Cr | ₹5,931.00 Cr | ₹8,738.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹-117.00 Cr | ₹-183.00 Cr | ₹95.00 Cr | ₹487.00 Cr | ₹1,231.00 Cr | ₹1,670.00 Cr | |
| Investing cash flow | — | — | — | — | — | ₹-2,724.80 Cr |
| ₹-16.00 Cr | ₹604.00 Cr | ₹2,777.00 Cr | ₹-722.00 Cr | ₹-535.00 Cr | ₹1,201.00 Cr | |
| Capital expenditure | ₹-111.00 Cr | ₹-248.00 Cr | ₹-413.00 Cr | ₹-438.00 Cr | ₹-427.00 Cr | ₹-828.00 Cr |
| End cash position | — | — | — | — | — | ₹973.30 Cr |
Change in working capital, Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 25–Dec 25(2Q) | Mar 26 | Jun 26 |
|---|---|---|---|
| Promoter | 17.57% | 17.55% | 17.53% |
| Public | 82.01% | 82.03% | 82.05% |
| Employee trusts | 0.42% | 0.42% | 0.42% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
31 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.